Real-time Stock quotes, portfolio, LIVE TV and more.
|
Sep 08, 2012, 12.39 PM IST
Shares of pharmaceutical and healthcare company Wockhardt has touched a 52-week high of Rs 1,352.80 on Saturday after the DNA reported that the company has received approval from the US Food and Drug Administration (US FDA) for Schizophrenia Medication Ziprasidone Hyrochloride.
Shares of pharmaceutical and healthcare company Wockhardt has touched a 52-week high of Rs 1,352.80 on Saturday after the DNA reported that the company has received approval from the US Food and Drug Administration (US FDA) for Schizophrenia Medication Ziprasidone Hyrochloride.
In previous month, it had received tentative approval for marketing a generic version of 20 mg, 40 mg, 60 mg and 80 mg capsules containing Ziprasidone hydrochloride, which is used in the treatment of bipolar disorders and schizophrenia. Ziprasidone capsule is the generic name for the brand Geodon, marketed in the US by Pfizer.
According to the IMS Health, the total market for this product in the US is about USD 1.3 billion.
Related News Set email alert for |
Action in Wockhardt
News Videos
|